Rheumatoid Arthritis

A First in Class Product that can act as a “Platform” Applicable to Multiple Diseases

In Vivo Demonstration of Tolerogenic Potency
of ImmCelz® in Rheumatoid Arthritis

12 mice where used per group. ImmCelz® was addadministered to mice 14 days after last collagen injection. Control ( diamond ) mice had rapid onset of disease. 100,000 inactive ImmCelz® cells (square). Administration of 100,000 active ImmCelz® cells (X) resulted in disease protection. Depletion of T regulatory cells by removal of CD25 positive cells resulted in negation of protection (triangle).

Graphic 1.1

Suppression of Innate Immunity: ImmCelz® Inhibits
TNF-alpha Production from Activated Macrophages

Allogeneic peripheral blood mononuclear cells (PBMC) were incubated with umbilical cord mesenchymal stem cells for 48 hours in a transwell chamber and subsequently added to lipopolysaccharide stimulated macrophages at a 1:1 ratio. Assessment of TNF-alpha was performed by ELISA at the indicated time points

Graphic 2.1